Cleveland Diagnostics

When it comes to prostate cancer testing, accuracy is crucial for early detection and timely treatment. IsoPSA goes beyond standard PSA tests by identifying structural changes in PSA proteins that may be linked to cancer and, in doing, so more accurately assesses risk of clinically significant prostate cancer. This approach enables clinicians to make more informed biopsy decisions, helping to ensure patients receive the right care at the right time. Learn more: https://hubs.la/Q03fRwDp0

#ICYMI we recently announced that our IsoPSA test is officially available nationwide through Quest Diagnostics! This expanded access is a major development in providing patients and physicians with a more accurate approach to assessing #prostatecancer risk. Learn more: https://hubs.ly/Q03fBBcn0

#ICYMI our VP of R&D, Erez Podoly, PhD, recently shared his perspective on what 2025 holds for the #biopharma industry, emphasizing the ongoing shift toward precision medicine. As we advance more accurate methods for assessing the risk of clinically significant #prostatecancer, we're proud to be part of the movement that empowers clinicians to deliver more precise, patient-centered care. By improving diagnostic test development and delivery, we’re contributing to a future of personalized disease management and care, ensuring better outcomes for patients. Read the full article here: https://hubs.la/Q03bx6320 Citeline

IsoPSA clarifies #prostatecancer risk by assessing structural differences in PSA proteins that are expressed by cancer. This approach is a more specific measure of #prostatecancer, helping to identify men who would benefit from a biopsy and those who would not. Learn more about IsoPSA: https://hubs.la/Q03bxnCH0

For the latest news, updates, and insights specific to IsoPSA and #prostatecancer testing, be sure to follow our dedicated IsoPSA LinkedIn page at https://hubs.la/Q03bxqnR0.

#ICYMI Dr. Aaron Berger, Chief Medical Officer and Director of Clinical Research of Associated Urological Specialists (AUS), shared his perspective on the changing landscape of prostate cancer screening and diagnosis in a recent article on MedCity News. Dr. Berger discussed the often lengthy and complex journey to a prostate cancer diagnosis, underscoring the importance of providing physicians with options to navigate the process following an elevated PSA result. He emphasized the opportunity for innovation in prostate cancer diagnostics, stressing that effective screening can significantly impact patient outcomes. As we strive to improve accuracy in prostate cancer testing, we take pride in being part of the innovative progress in the field. Enhanced accuracy ensures timely diagnoses and better outcomes, and we remain committed to advancing patient care and driving impactful change in #prostatecancer testing. Read his insights here: https://hubs.la/Q03bxyr90

#DidYouKnow that our IsoPSA test is a more accurate approach to assessing the risk of having clinically significant prostate cancer (csPCa)? By delivering more than twice the specificity of total PSA (tPSA) and over three times that of %free PSA, IsoPSA adds clarity to #prostatecancer testing. Learn more at https://hubs.la/Q03bxmh_0.

Our Manager, Business Development, Dustin Dressel, is excited to engage with fellow professionals and industry leaders and explore key issues in #urology practice and clinical management at LUGPA's Regional Meeting this week, March 14-15, in Houston. If you’re attending, stop by Booth 8 and say hello! We’d love to connect and discuss how we can collaborate to advance the future of patient care together! #LUGPARegional #LUGPA2025

This #PatientSafetyAwarenessWeek, we’re highlighting the importance of accurate prostate cancer diagnoses in ensuring patient safety. When test results are precise, healthcare providers can make informed decisions, leading to better, more personalized care. Our IsoPSA test provides physicians with clear, actionable results that are essential to inform prostate biopsy decisions, for better and more timely treatment. Learn more about accurate prostate cancer testing at https://hubs.la/Q03bwQ5h0. #PSAW #PSAW25

Auburn University football coach Hugh Freeze's prostate cancer diagnosis serves as a powerful reminder of the importance of regular screenings and early, accurate detection. Prostate cancer often develops without obvious symptoms, making it crucial to detect the disease before it advances. Ancillary testing options, like the IsoPSA test, can provide enhanced clarity to prostate cancer diagnoses, offering men the opportunity to pursue the most effective treatment options and improve their chances of successful recovery. Thanks to early detection, Hugh is continuing his coaching duties while undergoing treatment and is expected to make a full recovery. Read his story featured on ESPN to understand why #proactivehealth measures matter: https://lnkd.in/eWGFdd3g #prostatecancer #survivorship #earlydetection